Group sequential testing for cluster randomized trials with time-to-event endpoint

被引:0
|
作者
Li, Jianghao [1 ]
Jung, Sin-Ho [1 ]
机构
[1] Duke Univ, Dept Biostat & Bioinformat, Sch Med, Durham, NC 27705 USA
关键词
alpha spending function; dependent increment; expected sample size; intracluster correlation coefficient; log-rank test; variable cluster size; MAXIMUM DURATION; LOGRANK TESTS; DESIGN;
D O I
10.1111/biom.13498
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
We propose group sequential methods for cluster randomized trials (CRTs) with time-to-event endpoint. The alpha spending function approach is used for sequential data monitoring. The key to this approach is determining the joint distribution of test statistics and the information fraction at the time of interim analysis. We prove that the sequentially computed log-rank statistics in CRTs do not have independent increment property. We also propose an information fraction for group sequential trials with clustered survival data and a corresponding sample size determination approach. Extensive simulation studies are conducted to evaluate the performance of our proposed testing procedure using some existing alpha spending functions in terms of expected sample size and maximal sample size. Real study examples are taken to demonstrate our method.
引用
收藏
页码:1353 / 1364
页数:12
相关论文
共 50 条
  • [21] Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint
    Huang, Bo
    Talukder, Enayet
    Han, Lixin
    Kuan, Pei-Fen
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2019, 29 (01) : 189 - 202
  • [22] Familywise error for multiple time-to-event endpoints in a group sequential design
    Thomsen, Henrik F.
    Lausvig, Nanna L.
    Pipper, Christian B.
    Andersen, Soren
    Damgaard, Lars H.
    Emerson, Scott S.
    Ravn, Henrik
    [J]. STATISTICS IN MEDICINE, 2024, 43 (18) : 3417 - 3431
  • [23] Guidelines for the definitions of time-to-event endpoints in randomized clinical trials: Results of the datecan project for breast group
    Gourgou-Bourgade, S.
    Dabakuyo-Yonli, S.
    Cameron, D.
    Cardoso, F.
    Poortmans, P.
    Asselain, B.
    Azria, D.
    [J]. CANCER RESEARCH, 2013, 73
  • [24] Guidelines for the definitions of time-to-event endpoints in randomized clinical trials: Results of the DATECAN Project for Breast Group
    Gourgou, Sophie
    Dabakuyo, Tienhan Sandrine
    Asselain, Bernard
    Azria, David
    Cameron, David A.
    Cardoso, Fatima
    Poortmans, Philip M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] A proportional risk model for time-to-event analysis in randomized controlled trials
    Kuss, Oliver
    Hoyer, Annika
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2021, 30 (02) : 411 - 424
  • [26] Analysis of a composite endpoint with longitudinal and time-to-event data
    Tseng, Chi-hong
    Wong, Weng Kee
    [J]. STATISTICS IN MEDICINE, 2011, 30 (09) : 1018 - 1027
  • [27] Statistical Testing of Single and Multiple Endpoint Hypotheses in Group Sequential Clinical Trials
    Huque, Mohammad
    Mushti, Sirisha
    Alosh, Mohamed
    [J]. BIOPHARMACEUTICAL APPLIED STATISTICS SYMPOSIUM, VOL 3: PHARMACEUTICAL APPLICATIONS, 2018, : 119 - 149
  • [28] Development of a time-to-event endpoint for use in premanifest Huntington's disease (HD) clinical trials
    Rossomanno, S.
    Guthrie, H.
    Wild, E. J.
    Schobel, S. A.
    Boak, L.
    Trundell, D.
    [J]. MOVEMENT DISORDERS, 2020, 35 : S102 - S102
  • [29] Bayesian group sequential designs for cluster-randomized trials
    Shen, Junwei
    Golchi, Shirin
    Moodie, Erica E. M.
    Benrimoh, David
    [J]. STAT, 2022, 11 (01):
  • [30] Quantification of follow-up time in oncology clinical trials with a time-to-event endpoint: Asking the right questions
    Rufibach, Kaspar
    Grinsted, Lynda
    Li, Jiang
    Weber, Hans Jochen
    Zheng, Cheng
    Zhou, Jiangxiu
    [J]. PHARMACEUTICAL STATISTICS, 2023, 22 (04) : 671 - 691